References of "Henrotin, Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAnalgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Sahebkar, A; Henrotin, Yves ULg

in Pain Medicine : The Official Journal of the American Academy of Pain Medicine (in press)

Background. Curcuminoids are natural products with potent anti-inflammatory and antioxidant properties. There have been a number of reports on the analgesic effects of curcuminoids in clinical trials, yet ... [more ▼]

Background. Curcuminoids are natural products with potent anti-inflammatory and antioxidant properties. There have been a number of reports on the analgesic effects of curcuminoids in clinical trials, yet data have not been fully conclusive. Objectives. To provide the highest level of evidence on the efficacy of curcuminoids in patients with painful conditions through meta-analysis of data from randomized controlled trials (RCTs). Methods. A systematic review and meta-analysis was conducted using data reported by RCTs. The primary efficacy measure was pain intensity or algofunctional status. Treatment effect was summarized with standardized mean difference (SMD) calculated from differences in means of pain measures between treatment and control groups using a random-effects model. Results. A total of eight RCTs met our inclusion criteria that included 606 randomized patients. Curcuminoids were found to significantly reduce pain (SMD: −0.57, 95% CI: −1.11 to −0.03, P = 0.04). This pain-relieving effect was found to be independent of administered dose and duration of treatment with curcuminoids, and was free from publication bias. Curcuminoids were safe and well tolerated in all evaluated RCTs. Conclusion. Curcuminoids supplements may be a safe and effective strategy to improve pain severity, by warranting further rigorously conducted studies to define the long-term efficacy and safety. [less ▲]

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailReview of soluble biomarkers of osteoarthritis: lessons from animal model
Legrand, Catherine ULg; Lambert, Cécile ULg; Comblain, Fanny ULg et al

in Osteoarthritis and Cartilage (2016, April), 24(suppl 1), 88

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritic sclerotic subchondral osteoblasts secreted elevated concentration of fibulin-3 fragments in vitro
Sanchez, Christelle ULg; Lambert, Cécile ULg; Comblain, Fanny ULg et al

in Osteoarthritis and Cartilage (2016, April), 24(suppl 1), 83

Detailed reference viewed: 22 (5 ULg)
Full Text
Peer Reviewed
See detailFibulin-3 fragments are prognostic biomarkers of osteoarthritis incidence in overweight and obese women
Runhaar, Jos; Sanchez, Christelle ULg; Taralla, Sébastien et al

in Osteoarthritis Cartilage (2016), 24(4), 672-678

OBJECTIVE: To determine the association between three fibulin-3 peptides and the incidence of radiographic and clinical knee osteoarthritis (OA). DESIGN: Women between 50 and 60 years, with a BMI >/=27 kg ... [more ▼]

OBJECTIVE: To determine the association between three fibulin-3 peptides and the incidence of radiographic and clinical knee osteoarthritis (OA). DESIGN: Women between 50 and 60 years, with a BMI >/=27 kg/m2, free of knee OA, were recruited. Using binary logistic regression, the association between baseline concentration of serum fibulin (Fib)3-1, Fib3-2 and Fib3-3 and incidence of clinical and radiographic knee OA after 30 months of follow-up was evaluated. RESULTS: Baseline and follow-up measurements were available for 241 women with a mean age of 55.9 +/- 3.2 years and mean BMI of 31.7 +/- 3.6 kg/m2. None of the concentrations of the three Fib3 epitopes were associated with the incidence of medial or lateral joint space narrowing (JSN) >/=1.0 mm or the incidence of Kellgren & Lawrence (K&L) grade >/=2 after 30 months. All three Fib3 epitopes were associated with the incidence of the clinical and radiographic ACR-criteria and Fib3-1 and Fib3-3 also with chronic pain at follow-up. When adjusted for the other Fib3 peptide concentrations, only Fib3-1 was significantly associated to the incidence of the American College of Rheumatology (ACR)-criteria (OR 3.2 [1.2-8.7]) and chronic pain at follow-up (OR 3.0 [1.2-7.7]). CONCLUSIONS: Baseline fibulin-3 concentrations are associated with the incidence of clinical knee OA among middle-aged overweight and obese women. Therewith, they meet the criteria of a prognostic biomarker according to the BIPED biomarker classification for OA. Further validation of the fibulin-3 epitopes seems warranted in order to better distinguish subgroups of individuals at increased risk for knee OA development. [less ▲]

Detailed reference viewed: 15 (4 ULg)
Full Text
See detailBien soigner l'arthrose: un enjeu de société
Henrotin, Yves ULg

Conference (2016, February 04)

Detailed reference viewed: 38 (1 ULg)
Full Text
See detailBiomarqueurs dans l'arthrose et acide hyaluronique
Henrotin, Yves ULg

Conference (2016, January 16)

Detailed reference viewed: 21 (0 ULg)
Full Text
See detailBien soigner l'arthrose: un enjeu capital pour notre société!
Henrotin, Yves ULg

Conference (2016, January 07)

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailLes croyances délétères des patients lombalgiques : revue narrative de la littérature
Demoulin, Christophe ULg; Roussel, Nathalie; Marty, Marc et al

in Revue Médicale de Liège (2016), 71(1), 40-46

Detailed reference viewed: 213 (18 ULg)
Full Text
Peer Reviewed
See detailReview of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014
Comblain, Fanny ULg; Serisier, Samuel; Barthelemy, Nicolas ULg et al

in Journal of Veterinary Pharmacology & Therapeutics (2016), 39

Detailed reference viewed: 137 (7 ULg)
Full Text
Peer Reviewed
See detailCombined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
Hochberg, M. C.; Martel-Pelletier, J.; Monfort, J. et al

in Ann Rheum Dis (2016), 75(1), 37-44

OBJECTIVES: To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. METHODS: Double-blind ... [more ▼]

OBJECTIVES: To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. METHODS: Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score >/=301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D. RESULTS: The adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups. CONCLUSIONS: CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. TRIAL REGISTRATION NUMBER: NCT01425853. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailRandomized, Double-Blinded, Controlled Clinical Trial Evaluating the Efficacy of a Diet Supplemented with Curcuminoids Extract, Hydrolysed Collagen and Green Tea Extract in Dogs with Osteoarthritis
Barthélémy, Nicolas; Comblain, Fanny ULg; Lesponne, Isabelle et al

in Veterinary and Comparative Orthopaedics and Traumatology (2016)

Detailed reference viewed: 28 (1 ULg)
Full Text
Peer Reviewed
See detailArthrose rachidienne lombaire: une réalité? comment la définir?
Henrotin, Yves ULg

Conference (2015, December 15)

Detailed reference viewed: 26 (0 ULg)
Full Text
See detailSyndrome metabolique: prise en charge par le kinésithérapeute
Henrotin, Yves ULg

Conference (2015, December 13)

Detailed reference viewed: 21 (0 ULg)
Full Text
See detailHa INTRAARTICULAR INJECTION: THERAPEUTIC AND ECONOMIC CONSIDERATIONS
Henrotin, Yves ULg

Conference (2015, December 12)

Detailed reference viewed: 11 (0 ULg)
Full Text
See detailLes marqueurs biologiques de l'arthrose : de la découverte à l'industrialisation
Henrotin, Yves ULg

Scientific conference (2015, December 04)

Detailed reference viewed: 13 (0 ULg)